Opsona Therapeutics

Opsona Therapeutics

Opsona Therapeutics logo

Opsona Therapeutics is a biotechnology company that was founded in 2004 and is based in Dublin, Ireland. The company focuses on the development of novel therapeutic approaches for the treatment of inflammatory diseases and cancer. Opsona Therapeutics is particularly known for its work on the innate immune system, specifically targeting Toll-like receptors (TLRs) and other components of the immune response.

History

Opsona Therapeutics was established as a spin-out from Trinity College Dublin, leveraging research conducted by its founders in the field of immunology. The company was co-founded by Professor Luke O'Neill, Professor Dermot Kelleher, and Dr. Kingston Mills, who are all prominent figures in the field of immunology and have contributed significantly to the understanding of the innate immune system.

Research and Development

Opsona Therapeutics has focused its research on the modulation of the innate immune system to develop treatments for a variety of diseases. The company's primary area of interest is the inhibition of Toll-like receptors, which play a crucial role in the activation of the innate immune response. By targeting these receptors, Opsona aims to develop therapies that can modulate the immune system's response to inflammation and infection.

One of the key products developed by Opsona is OPN-305, a monoclonal antibody that targets Toll-like receptor 2 (TLR2). OPN-305 has been investigated for its potential use in preventing organ transplant rejection and treating other inflammatory conditions.

Clinical Trials

Opsona Therapeutics has conducted several clinical trials to evaluate the safety and efficacy of its lead product, OPN-305. These trials have explored the use of OPN-305 in various clinical settings, including kidney transplantation and myelodysplastic syndromes. The results of these trials have provided valuable insights into the potential therapeutic applications of TLR2 inhibition.

Partnerships and Collaborations

Opsona has engaged in various partnerships and collaborations to advance its research and development efforts. The company has collaborated with academic institutions, research organizations, and pharmaceutical companies to explore new therapeutic avenues and expand its scientific knowledge base.

Related Pages

• Biotechnology
• Immunology
• Monoclonal antibody
• Toll-like receptor
• Innate immune system